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There has always been controversy about the value of several new (and 
expensive) methods of investigating 
disease, particularly cancer. The 
argument which has been accepted by 
most physicians has always been that 
the earlier diagnosis is made, the better 
the prognosis.  We feel much happier 
when we can remove an obvious 
cancerous mass, and have relied on the 
concept of ‘disease-free interval’ as the 
benchmark of success.
If advanced diagnostic techniques 
had no other drawback apart from 
cost to the community, this argument 
seemed reasonable enough. However, 
voices against such a blanket approach 
have become more strident in recent 
years. 
A recent article in Scientific 
American, the sort of journal laypersons 
as well as practitioners give credence 
to, has highlighted the case against this 
approach.1 These arguments may be 
summarised as follows:
1. A number of ‘cancer diagnostic’ 
tests, including mammography 
and tests for prostate cancer, the 
two most common cancers in 
the western world, have serious 
effects on patients without saving 
their lives. As an example, of the 
40 million mammograms carried 
out in the US every year, 138,000 
discovered breast cancer, but 
this diagnosis did not help up to 
134,000 (97%) of them. Most of 
these tumours were either very 
slow-growing, or would have been 
detected anyway later on without a 
deleterious effect, or else they were 
so aggressive that no treatment 
would have been of any long-term 
value. It has been suggested by 
the U.S. Preventive Services Task 
Force (2009) that mammograms 
should be performed at a later stage 
and less frequently than previously 
recommended.
2. Chest X-rays have come under 
similar criticism, in that tumours 
have appeared within a couple of 
months of the examination. And 
therefore were not effective in 
preventing the disease.
3. PSA (Prostate  Specific Antigen) 
has now been practically relegated 
to the assessment of patients with 
established prostate cancer, and has 
all but lost its lustre as a screening 
test for this condition.
It would indeed be a mistake to 
conclude that such tests are irrelevant. 
The conclusion to be drawn is that 
selection of patients for examination 
should be based on clearly indicated 
medical conditions, and not used as a 
blanket screening program. 
Related to this is the concept of 
‘quality of life’ as opposed to ‘disease-
free interval’. Months of misery 
endured by patients on radiation or 
chemotherapy are justified only if the 
eventual quality of life justifies the 
procedures. 
One could argue that saving even a 
single life out of thousands screened is 
a worthwhile exercise. However, against 
this, one has to keep in mind that a 
diagnosis of serious disease brings with 
it, at the very least, a great deal of worry, 
not to mention physical discomfort from 
complications of the treatment itself. This 
is justifiable only if the benefits obtained 
from early diagnosis render the side-
effects acceptable calculated risks. 
If such problems are serious enough 
for somatic diseases, they are even more 
pronounced for genetic disorders. There 
is simply no justification of undertaking 
complex diagnostic genetic procedures 
where there is no foreseeable cure, or 
where available modalities of treatment 
are not available or allowed in this country.  
This is becoming more and more relevant 
in view of the very real possibility that in 
the near future we are likely to possess 
extensive knowledge of our own genome 
with all its blemishes and possible genetic 
abnormalities. It is well to bear in mind that 
while all patients have the right to know, 
they also have the right not to know all the 
gory details relating to their disease, or 
tendency to disease.
Dissuading patients from over-
investigating themselves, like over-
indulging in various medicinals for all 
sorts of imagined conditions, may be 
an up-hill battle. Such tests are likely 
to become more and more easily 
available, and could very easily lead to 
misinterpretation and over-treatment.  
Genetic tests are available on the 
internet.  In Australia, there is currently 
a move to have nurses perform X-rays. 
There is much scope and considerable 
financial incentive for control of medical 
tests to be taken away from medical 
supervision.  This I believe is a mistake, 
not because non-medical persons cannot 
be trained to read an X-ray or perform 
a genetic test, but primarily because 
no medical test should be interpreted 
otherwise than in the milieu of medical 
practice, where symptoms, signs and 
ancillary examinations are integrated into 
one meaningful whole. 
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